Skip to main content
RT @drdavidliew: Does curcurmin (tumeric) do anything in RA?
Big talk & sales.

Best chance would be keeping pts in

David Liew drdavidliew

3 years 11 months ago
Does curcurmin (tumeric) do anything in RA? Big talk & sales. Best chance would be keeping pts in remission during csDMARD taper: DBRCT n=200 52w, high bioavail form, good serum conc Absolutely nothing vs placebo I'll call it: just doesn't work in RA ABST1587 #ACR22 @RheumNow https://t.co/wecEfkXT55
RT @RichardPAConway: Flood @FloodRachael et al. ULT reduces non-episodic foot pain in hyperuricaemic patients who fail t

Richard Conway RichardPAConway

3 years 11 months ago
Flood @FloodRachael et al. ULT reduces non-episodic foot pain in hyperuricaemic patients who fail to meet gout classification criteria. Predicted by double counter or tophus on US. @RheumNow #ACR22 Abstr#1828 https://t.co/iOy0Vo5HVO https://t.co/vF98DFB7hJ
RT @RichardPAConway: McCormick et al Fruit juice and other sugar-sweetened drinks increase gout flare in dose-dependent

Richard Conway RichardPAConway

3 years 11 months ago
McCormick et al Fruit juice and other sugar-sweetened drinks increase gout flare in dose-dependent manner @RheumNow #ACR22 Abstr#1805 https://t.co/aGg5i5XyTK https://t.co/x8ChwASM6P
A Novel Treatment Response Measurement Tool for Lupus

Dr. Dao discusses abstract 2054 with Dr. Morand at the #ACR22 Co

Dr. John Cush RheumNow

3 years 11 months ago
A Novel Treatment Response Measurement Tool for Lupus Dr. Dao discusses abstract 2054 with Dr. Morand at the #ACR22 Convergence. Abstract 2054: Towards a Novel Clinician-Reported Outcome Measure for SLE – Outcomes of an International Consensus Process. https://t.co/iqqyI953Vz https://t.co/taUjTHsrJ2
RT @drdavidliew: Even young SLE patients are still at high risk of severe COVID:
- in general pop, age is key factor
- i

David Liew drdavidliew

3 years 11 months ago
Even young SLE patients are still at high risk of severe COVID: - in general pop, age is key factor - in SLE, risk is high across age groups (maybe due to both meds & disease) - vaccination makes a big diff but SLE pts still at high risk ABST1591 @CCalabreseDO #ACR22 @RheumNow https://t.co/ra1F79ITn3
RheumNow’s expanded coverage of the #ACR22 annual meeting is sponsored in part by Novartis. All content chosen by Rhe

Dr. John Cush RheumNow

3 years 11 months ago
RheumNow’s expanded coverage of the #ACR22 annual meeting is sponsored in part by Novartis. All content chosen by RheumNow & its faculty.
Vaccine efficacy remains an important and highly discussed topic at this year’s annual meeting given the ongoing COVID-19 global health crisis, current influenza season, and recently published 2022 ACR guidelines for vaccinations in patients with rheumatic and musculoskeletal diseases.
RT @Yuz6Yusof: #ACR22 Abstr#1830 Short attack of arthritis episode is common in Familial Mediterranean Fever. Other poin

Md Yuzaiful Md Yusof Yuz6Yusof

3 years 11 months ago
#ACR22 Abstr#1830 Short attack of arthritis episode is common in Familial Mediterranean Fever. Other pointers? A cohort study in Turkey showed to consider FMF in pts with red mono-oligo arthritis in lower limbs & spondyloarthropathy. 20% were colchicine resistant @RheumNow https://t.co/JXGcgCrhPu
RT @Yuz6Yusof: #ACR22 Abstr#1839 "Doctor, I have fever & recurrent right-sided tummy pain, is it my appendix?" A cas

Md Yuzaiful Md Yusof Yuz6Yusof

3 years 11 months ago
#ACR22 Abstr#1839 "Doctor, I have fever & recurrent right-sided tummy pain, is it my appendix?" A case-control study in Turkey reported 16% of unindicated appendectomies prior to FMF diagnosis. This group had late diagnosis and associated with M694V homozygous mutation @RheumNow https://t.co/QtxjuHDXYC
RT @RichardPAConway: FitzGerald et al. PsA patients with higher levels of IL-23-IL-17 pathway biomarkers more likely to

Richard Conway RichardPAConway

3 years 11 months ago
FitzGerald et al. PsA patients with higher levels of IL-23-IL-17 pathway biomarkers more likely to benefit from TYK2i deucravacitinib @RheumNow #ACR22 Abstr#2133 https://t.co/eVq4XQgX5l https://t.co/HZlTS5OZ2s
RT @RichardPAConway: Maughan et al inc the late, great, Justin Mason. Treatment cessation in TAK. Feasible in some patie

Richard Conway RichardPAConway

3 years 11 months ago
Maughan et al inc the late, great, Justin Mason. Treatment cessation in TAK. Feasible in some patients. Initial treatment response, age and Numanotype V arterial involvement predictors. @RheumNow #ACR22 Abstr#L017 https://t.co/5t00prCtFT https://t.co/GGUUNQqyoL
RT @RichardPAConway: Terrier @TerrierBen et al. PNEUMOVAS -pneumococcal vaccination in AAV treated with RTX Double dose

Richard Conway RichardPAConway

3 years 11 months ago
Terrier @TerrierBen et al. PNEUMOVAS -pneumococcal vaccination in AAV treated with RTX Double dose of PCV13 at day 0 and day 7 followed by single dose of PPV23 at month 5 significantly improves antibody responses (2 in figure) @RheumNow #ACR22 Abstr#L016 https://t.co/qKqgvv7ZwI https://t.co/UHCuZNSF54
×